Crinetics Pharmaceuticals reported positive topline results for the ACROBAT Edge and Evolve Phase 2 trials of oral paltusotine for acromegaly and received Rare Pediatric Disease Designation for CRN04777 for congenital hyperinsulinism. The company's research and development expenses increased, as did general and administrative expenses, leading to a higher net loss compared to the same period in the previous year. Cash, cash equivalents, and investments totaled $186.8 million.